|
Malignant neoplasm of lung
|
0.380 |
Biomarker
|
disease |
BEFREE |
Recent clinical trials on NK cell-based novel therapies such as cytokines including interleukin (IL)-15, IL-12 and IL-2, NK-92 cell lines and allogenic NK cell immunotherapy showed promising results with less adverse effects on the lung cancer survival.
|
29616326 |
2018 |
|
Malignant neoplasm of lung
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
The association between lung cancer incidence and survival and 23 polymorphisms descriptive of 11 inflammation-related genes (interferon gamma gene [IFNG], interleukin 10 gene [IL10], interleukin 1 alpha gene [IL1A], interleukin 1 beta gene [IL1B], interleukin 2 gene [IL2], interleukin 4 receptor gene [IL4R], interleukin 4 gene [IL4], interleukin 6 gene [IL6], prostaglandin-endoperoxide synthase 2 gene [PTGS2] (also known as COX2), transforming growth factor beta 1 gene [TGFB1], and tumor necrosis factor alpha gene [TNFA]) was evaluated.
|
29408308 |
2018 |
|
Malignant neoplasm of lung
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Conditional logistic regression models adjusting for serum cotinine concentrations were used to estimate odds ratios for lung cancer risk associated with concentrations of interleukin (IL)-1β, IL-2, IL-6, IL-8, IL-10, IL-12, interferon γ, tumor necrosis factor α, and granulocyte-macrophage colony-stimulating factor.
|
27998891 |
2017 |
|
Malignant neoplasm of lung
|
0.380 |
Biomarker
|
disease |
BEFREE |
All of the data indicated that immunochemotherapy of 5-FU and IL-2 may provide a new treatment option for patients with lung cancer.
|
24935593 |
2014 |
|
Malignant neoplasm of lung
|
0.380 |
Therapeutic
|
disease |
CTD_human |
EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: a case report.
|
18625569 |
2009 |
|
Malignant neoplasm of lung
|
0.380 |
Therapeutic
|
disease |
CTD_human |
Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
|
18298334 |
2008 |
|
Malignant neoplasm of lung
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
We investigated whether combined treatment with GM-CSF and IL-2 induced macrophage-mediated antitumor activity and/or T-cell-mediated antitumor activity in lung cancer patients.
|
11129324 |
2000 |
|
Malignant neoplasm of lung
|
0.380 |
Biomarker
|
disease |
BEFREE |
Normal peripheral blood mononuclear cells (PBMC) were co-cultured with a human lung cancer cell line (LC89) transduced with the interleukin-2 (IL-2), IL-7, granulocyte-macrophage colony-stimulating factor (GM-CSF), and tumor necrosis factor-alpha (TNF-alpha) genes to evaluate the capacity of the engineered cells to: allow survival of CD3+ and CD56+ cells, generate cytotoxic effectors with HLA class I restricted and unrestricted antitumor activity, and interfere in the molecular organization of the CD3/T-cell receptor associated signal transduction machinery.
|
8978294 |
1997 |
|
Malignant neoplasm of lung
|
0.380 |
Biomarker
|
disease |
BEFREE |
These data suggest a potentially useful but limited clinical role of Adex1CAhIL-2 in gene therapy for lung cancer patients.
|
8989990 |
1997 |
|
Malignant neoplasm of lung
|
0.380 |
Therapeutic
|
disease |
CTD_human |
Interferon-gamma and interleukin-2 suppress the experimental metastasis of mouse renal adenocarcinoma.
|
7614408 |
1995 |
|
Malignant neoplasm of lung
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the cytolytic activity of peripheral blood T-cells (PBT) obtained from nine patients with primary lung cancer treated by surgical adjuvant adoptive immunotherapy (AIT) with lymphokine-activated killer cells and low-dose recombinant interleukin 2 at the time of rebound lymphocytosis (24-48 h after AIT).
|
1997188 |
1991 |